{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:21:01Z","timestamp":1780503661237,"version":"3.54.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308802"],"award-info":[{"award-number":["2023YFC2308802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308802"],"award-info":[{"award-number":["2023YFC2308802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308802"],"award-info":[{"award-number":["2023YFC2308802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01721-z","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T05:00:22Z","timestamp":1754888422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury"],"prefix":"10.1007","volume":"25","author":[{"given":"Haorui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"12","key":"1721_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1\u201311.","journal-title":"Exp Mol Med"},{"issue":"6","key":"1721_CR2","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin E, Michot J-M, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2(6):100170. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100170.","journal-title":"JHEP Rep"},{"key":"1721_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-related adverse events (Iraes): diagnosis, management, and clinical pearls. Current Oncol Rep. 2020. https:\/\/doi.org\/10.1007\/s11912-020-0897-9.","journal-title":"Current Oncol Rep"},{"issue":"1","key":"1721_CR4","doi-asserted-by":"crossref","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","volume":"10","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely JR Jr, McGuigan B, Chandra S, Fenton SE, Chowdhary A, Kennedy LB, Johnson DB. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology. 2021;10(1):1875639.","journal-title":"Oncoimmunology"},{"issue":"2","key":"1721_CR5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","volume":"15","author":"M Biewenga","year":"2021","unstructured":"Biewenga M, van der Kooij MK, Wouters M, Aarts MJB, van den Berkmortel F, de Groot JWB, Kapiteijn E. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol Int. 2021;15(2):510\u20139.","journal-title":"Hepatol Int"},{"issue":"23","key":"1721_CR6","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1002\/cncr.33165","volume":"126","author":"M Li","year":"2020","unstructured":"Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer. 2020;126(23):5088\u201397.","journal-title":"Cancer"},{"issue":"3","key":"1721_CR7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.32215","volume":"75","author":"M Li","year":"2022","unstructured":"Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS, Grover S. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022;75(3):531\u201340.","journal-title":"Hepatology"},{"issue":"1","key":"1721_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Molecular Sci. 2015;17(1):14. https:\/\/doi.org\/10.3390\/ijms17010014.","journal-title":"Int J Molecular Sci"},{"key":"1721_CR9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address, e.e.e., C. Clinical Practice Guideline Panel, m. Panel, and E.G.B. representative, EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol, 2019. 70(6): p. 1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"issue":"3","key":"1721_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","volume":"11","author":"YC Yu","year":"2017","unstructured":"Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM. CMA, CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hep Intl. 2017;11(3):221\u201341.","journal-title":"Hep Intl"},{"issue":"5","key":"1721_CR11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Fujishiro M. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hep Intl. 2021;15(5):1278\u201387.","journal-title":"Hep Intl"},{"issue":"6","key":"1721_CR12","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s12072-024-10688-0","volume":"18","author":"N Zhang","year":"2024","unstructured":"Zhang N, Li Z, Liu Y, Shi X, Shi Di, Li Y, Si X, Xun Z, Shao J, Zhao H, Wang H. Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hepatol Int. 2024;18(6):1770\u201380. https:\/\/doi.org\/10.1007\/s12072-024-10688-0.","journal-title":"Hepatol Int"},{"issue":"2","key":"1721_CR13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12328-022-01590-z","volume":"15","author":"S Kataoka","year":"2022","unstructured":"Kataoka S, Moriguchi M, Okishio S, Takahashi A, Okuda K, Seko Y, Itoh Y. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clin J Gastroenterol. 2022;15(2):467\u201374.","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"1721_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/liv.15340","volume":"43","author":"P Berry","year":"2023","unstructured":"Berry P, Kotha S, Zen Y, Papa S, El Menabawey T, Webster G, Heneghan M. Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort. Liver Int. 2023;43(1):147\u201354.","journal-title":"Liver Int"},{"key":"1721_CR15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","volume":"130","author":"NA Romanski","year":"2020","unstructured":"Romanski NA, Holmstroem RB, Ellebaek E, Svane IM. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. Eur J Cancer. 2020;130:211\u20138.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1721_CR16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2018;41(8):760\u20135.","journal-title":"Am J Clin Oncol"},{"key":"1721_CR17","doi-asserted-by":"crossref","first-page":"6391712","DOI":"10.1155\/2019\/6391712","volume":"2019","author":"K Imoto","year":"2019","unstructured":"Imoto K, Kohjima M, Hioki T, Kurashige T, Kurokawa M, Tashiro S, Ogawa Y. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol. 2019;2019:6391712.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"6","key":"1721_CR18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965\u201373.","journal-title":"Mod Pathol"},{"issue":"4","key":"1721_CR19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/flgastro-2021-101886","volume":"13","author":"PN Brennan","year":"2022","unstructured":"Brennan PN, Cartlidge P, Manship T, Dillon JF. Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI). Front Gastroenterol. 2022;13(4):332\u20136.","journal-title":"Front Gastroenterol"},{"issue":"1","key":"1721_CR20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","volume":"79","author":"M Cunningham","year":"2024","unstructured":"Cunningham M, Gupta R, Butler M. Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology. 2024;79(1):198\u2013212.","journal-title":"Hepatology"},{"issue":"12","key":"1721_CR21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Comm EG. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"4","key":"1721_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/ajco.12698","volume":"13","author":"K Roberts","year":"2017","unstructured":"Roberts K, Culleton V, Lwin Z, O\u2019Byrne K, Hughes BGM. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol. 2017;13(4):277\u201388.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"1721_CR23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","volume":"67","author":"HM McGuire","year":"2018","unstructured":"McGuire HM, Shklovskaya E, Edwards J, Trevillian PR, McCaughan GW, Bertolino P, Hersey P. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother. 2018;67(4):563\u201373.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1721_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","volume":"211","author":"R Ramesh","year":"2014","unstructured":"Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, Sundrud MS. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211(1):89\u2013104.","journal-title":"J Exp Med"},{"issue":"3","key":"1721_CR25","doi-asserted-by":"crossref","first-page":"e002337","DOI":"10.1136\/jitc-2021-002337","volume":"9","author":"ML Gauci","year":"2021","unstructured":"Gauci ML, Baroudjian B, Lebbe C, Roux O. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer. 2021;9(3):e002337.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1721_CR26","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5174","volume":"9","author":"K Arai","year":"2021","unstructured":"Arai K, Matsuda M, Nakayasu H, Meguro S, Kurokami T, Kubota A, Iwashita T. Nivolumab-induced liver injury with a steroid-refractory increase in biliary enzymes, in a patient with malignant mesothelioma: an autopsy case report. Clin Case Rep. 2021;9(12): e05174.","journal-title":"Clin Case Rep"},{"issue":"7","key":"1721_CR27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2217\/imt-2018-0187","volume":"11","author":"JRM Black","year":"2019","unstructured":"Black JRM, Goldin RD, Foxton M, Marafioti T, Akarca AU, Dalla Pria A, Pinato DJ. PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity. Immunotherapy. 2019;11(7):585\u201390.","journal-title":"Immunotherapy"},{"key":"1721_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0371-5","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson M-K, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. Jo ImmunoTherapy Cancer. 2018. https:\/\/doi.org\/10.1186\/s40425-018-0371-5.","journal-title":"Jo ImmunoTherapy Cancer"},{"key":"1721_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101619","volume":"28","author":"H Xing","year":"2023","unstructured":"Xing H, Wang Y, Qu B, Wei Q, Li C, Pan C, Li H. The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Transl Oncol. 2023;28: 101619.","journal-title":"Transl Oncol"},{"issue":"4","key":"1721_CR30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","volume":"10","author":"V Cheung","year":"2019","unstructured":"Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A, Cobbold JF. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Front Gastroenterol. 2019;10(4):364\u201371.","journal-title":"Front Gastroenterol"},{"issue":"9","key":"1721_CR31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","volume":"6","author":"JT Hlivko","year":"2008","unstructured":"Hlivko JT, Shiffman ML, Stravitz RT, Luketic VA, Sanyal AJ, Fuchs M, Sterling RK. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6(9):1036\u201340.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1721_CR32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Langman LJ. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2021;43(2):150\u2013200.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1721_CR33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","volume":"16","author":"JCA Broen","year":"2020","unstructured":"Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167\u201378.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"1721_CR34","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ymthe.2024.06.022","volume":"32","author":"CR Maldini","year":"2024","unstructured":"Maldini CR, Messana AC, Bendet PB, Camblin AJ, Musenge FM, White ML, Allen TM. Immunosuppressant therapy averts rejection of allogeneic\u2013Disrupted CAR-T cells. Mol Ther. 2024;32(10):3485\u2013503.","journal-title":"Mol Ther"},{"key":"1721_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01760","author":"A G\u00e9rard","year":"2020","unstructured":"G\u00e9rard A, Romani S, Van-Obberghen E, Fresse A, Muzzone M, Parassol N, Boscagli A, Rocher F, Borchiellini D, Drici M-D. Case report: successful treatment of steroid-refractory immune checkpoint inhibitor-related pure red cell aplasia with cyclosporin. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01760.","journal-title":"Front Oncol"},{"issue":"23","key":"1721_CR36","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2169\/internalmedicine.5216-20","volume":"59","author":"K Nakashima","year":"2020","unstructured":"Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, Ishizuka T. infliximab was found to be effective for treating immunosuppressive drug-resistant hepatitis due to Durvalumab. Intern Med. 2020;59(23):3055\u20139.","journal-title":"Intern Med"},{"issue":"3","key":"1721_CR37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000509953","volume":"14","author":"K Kanaoka","year":"2020","unstructured":"Kanaoka K, Moriizumi K, Okada H, Iwahashi K, Tsuji H, Yasuoka H, Minami S. Pembrolizumab-induced delayed-onset hepatitis. Case Rep Gastroenterol. 2020;14(3):586\u201392.","journal-title":"Case Rep Gastroenterol"},{"issue":"9","key":"1721_CR38","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"SK Yang","year":"2014","unstructured":"Yang SK, Hong M, Baek J, Choi H, Zhao WT, Jung YS, Song K. A common missense variant in confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017.","journal-title":"Nat Genet"},{"issue":"2","key":"1721_CR39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","volume":"16","author":"L Moi","year":"2021","unstructured":"Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Obeid M. Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol. 2021;16(2):318\u201326.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1721_CR40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CMR.0000000000000969","volume":"34","author":"AA Ozluk","year":"2024","unstructured":"Ozluk AA, Gunenc D, Yildirim SS, Karaca B. Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature. Melanoma Res. 2024;34(4):335\u201342.","journal-title":"Melanoma Res"},{"issue":"18","key":"1721_CR41","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2217\/imt-2019-0121","volume":"11","author":"CA Reddy","year":"2019","unstructured":"Reddy CA, Schneider BJ, Brackett LM, Tai AW. Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. Immunotherapy. 2019;11(18):1527\u201331.","journal-title":"Immunotherapy"},{"issue":"10","key":"1721_CR42","doi-asserted-by":"publisher","first-page":"e005635","DOI":"10.1136\/jitc-2022-005635","volume":"10","author":"A Coukos","year":"2022","unstructured":"Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M. Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. J ImmunoTherapy Cancer. 2022;10(10):e005635. https:\/\/doi.org\/10.1136\/jitc-2022-005635.","journal-title":"J ImmunoTherapy Cancer"},{"issue":"14","key":"1721_CR43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/imt-2023-0085","volume":"15","author":"SB Ali","year":"2023","unstructured":"Ali SB, Vembar P, Sukumaran S, Gunawardane D, Hughes T, Smith A. Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. Immunotherapy. 2023;15(14):1125\u201332.","journal-title":"Immunotherapy"},{"issue":"3","key":"1721_CR44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CRG Stroud","year":"2019","unstructured":"Stroud CRG, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, Walker P. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"17","key":"1721_CR45","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","volume":"15","author":"S Shinriki","year":"2009","unstructured":"Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, Ando Y. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009;15(17):5426\u201334.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1721_CR46","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300312","volume":"356","author":"SM Radwan","year":"2023","unstructured":"Radwan SM, Abdel-Latif GA, Abbas SS, Elmongy NF, Wasfey EF. The beneficial effects of l-carnitine and infliximab in methotrexate-induced hepatotoxicity: Emphasis on Notch1\/Hes-1 signaling. Arch Pharm (Weinheim). 2023;356(11): e2300312.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"4","key":"1721_CR47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2018;14(4):247\u20139.","journal-title":"J Oncol Pract"},{"issue":"1","key":"1721_CR48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","volume":"1","author":"M Corrigan","year":"2019","unstructured":"Corrigan M, Haydon G, Thompson F, Rajoriya N, Peplow CL, Hubscher SG, Armstrong MJ. Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report. Jhep Reports. 2019;1(1):66\u20139.","journal-title":"Jhep Reports"},{"key":"1721_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0484-x","volume":"7","author":"DH Johnson","year":"2019","unstructured":"Johnson DH, Zobniw CM, Trinh VA, Ma JS, Bassett RL, Abdel-Wahab N, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunotherapy Cancer. 2019;7:1\u20138.","journal-title":"J Immunotherapy Cancer"},{"issue":"9","key":"1721_CR50","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","volume":"29","author":"KD Chmiel","year":"2011","unstructured":"Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Kefford R. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29(9):e237\u201340.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1721_CR51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/imt.15.128","volume":"8","author":"T Nishihori","year":"2016","unstructured":"Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016;8(4):435\u201347.","journal-title":"Immunotherapy"},{"issue":"6","key":"1721_CR52","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","volume":"11","author":"J Bayry","year":"2023","unstructured":"Bayry J, Ahmed EA, Toscano-Rivero D, Vonniessen N, Genest G, Cohen CG, Mazer BD. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J Allergy Clin Immunolin Pract. 2023;11(6):1688\u201397.","journal-title":"J Allergy Clin Immunolin Pract"},{"issue":"15_suppl","key":"1721_CR53","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1200\/JCO.2017.35.15_suppl.3073","volume":"35","author":"M Ziemer","year":"2017","unstructured":"Ziemer M, Koukoulioti E, Simon J-C, Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Clin Oncol. 2017;35(15_suppl):3073\u20133073. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3073.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1721_CR54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000322298","volume":"84","author":"A Wree","year":"2011","unstructured":"Wree A, Dech\u00eane A, Herzer K, Hilgard P, Syn WK, Gerken G, Canbay A. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54\u20139.","journal-title":"Digestion"},{"issue":"17","key":"1721_CR55","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.12998\/wjcc.v9.i17.4415","volume":"9","author":"YW Tan","year":"2021","unstructured":"Tan YW, Chen L, Zhou XB. Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: a case report and review of the literature. World J Clin Cases. 2021;9(17):4415.","journal-title":"World J Clin Cases"},{"key":"1721_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001823","author":"X Li","year":"2022","unstructured":"Li X, Ji L, Li X, Sun D, Yang W. Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: case reports and review of the literature. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1001823.","journal-title":"Front Immunol"},{"issue":"3","key":"1721_CR57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","volume":"70","author":"M Riveiro-Barciela","year":"2019","unstructured":"Riveiro-Barciela M, Mu\u00f1oz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, Parra-L\u00f3pez R, Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol. 2019;70(3):564\u20136.","journal-title":"J Hepatol"},{"key":"1721_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1231597","author":"F Li","year":"2023","unstructured":"Li F, Wang T, Tang F, Liang J. Fatal acute-on-chronic liver failure following camrelizumab for hepatocellular carcinoma with HBsAg seroclearance: a case report and literature review. Front Med. 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1231597.","journal-title":"Front Med"},{"issue":"2","key":"1721_CR59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000507695","volume":"13","author":"T Thorsteinsdottir","year":"2020","unstructured":"Thorsteinsdottir T, Loitegard T, Reims HM, Porojnicu AC. Fatal cholestatic liver injury during treatment with PD1 immune checkpoint inhibitor for malignant melanoma: a case report. Case Rep Oncol. 2020;13(2):659\u201363.","journal-title":"Case Rep Oncol"},{"issue":"12","key":"1721_CR60","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.bbmt.2017.08.008","volume":"23","author":"K Reinhardt-Heller","year":"2017","unstructured":"Reinhardt-Heller K, Hirschberg I, Lang P, Vogl T, Handgretinger R, Bethge WA, Holzer U. Increase of intermediate monocytes in graft-versus-host disease: correlation with MDR1(+)Th17.1 levels and the effect of prednisolone and 1alpha,25-dihydroxyvitamin D3. Biol Blood Marrow Transplant. 2017;23(12):2057\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1721_CR61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","volume":"27","author":"W Li","year":"2016","unstructured":"Li W, Zhang H, Assaraf YG, Zhao K, Xue XJ, Xie JB, Chen ZS. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updates. 2016;27:14\u201329.","journal-title":"Drug Resist Updates"},{"issue":"4","key":"1721_CR62","first-page":"312","volume":"24","author":"F Bi","year":"1997","unstructured":"Bi F, Zhang XY, Fan DM. MRP gene and multidrug resistance of cancer. Pro Biochem Biophy. 1997;24(4):312\u20135.","journal-title":"Pro Biochem Biophy"},{"key":"1721_CR63","first-page":"5926609","volume":"2022","author":"H Xie","year":"2022","unstructured":"Xie H, Huang G, Zou J, Zhu Q, Liang Z, Huang X, Wu Q. The pharmacological mechanism of curcumin against drug resistance in non-small cell lung cancer: findings of network pharmacology and bioinformatics analysis. Evid Based Complement Alternat Med. 2022;2022:5926609.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"5","key":"1721_CR64","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2013.12.026","volume":"60","author":"A Eguchi","year":"2014","unstructured":"Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60(5):1063\u201374.","journal-title":"J Hepatol"},{"issue":"2","key":"1721_CR65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.26294","volume":"58","author":"DJ Antoine","year":"2013","unstructured":"Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Park BK. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777\u201387.","journal-title":"Hepatology"},{"issue":"6","key":"1721_CR66","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","volume":"147","author":"B Husain","year":"2021","unstructured":"Husain B, Kirchberger MC, Erdmann M, Sch\u00fcpferling S, Abolhassani AR, Fr\u00f6hlich W, Heinzerling L. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol. 2021;147(6):1623\u201330.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1721_CR67","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1016\/S1470-2045(18)30828-3","volume":"20","author":"F Martins","year":"2019","unstructured":"Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Obeid M. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20(1):E54\u201364.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1721_CR68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0976-9668.175016","volume":"7","author":"H Singh","year":"2016","unstructured":"Singh H, Grewal N, Arora E, Kumar H, Kakkar AK. Vedolizumab: a novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016;7(1):4\u20139.","journal-title":"J Nat Sci Biol Med"},{"issue":"5","key":"1721_CR69","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","volume":"377","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su CY, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis reply. N Engl J Med. 2017;377(5):496\u20137.","journal-title":"N Engl J Med"},{"key":"1721_CR70","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1038\/sj.bjp.0706400","volume":"147","author":"SM Lucas","year":"2006","unstructured":"Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147:S232\u201340.","journal-title":"Br J Pharmacol"},{"key":"1721_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86336","author":"SR Harrison","year":"2016","unstructured":"Harrison SR, McGonagle D, Nizam S, Jarrett S, van der Hilst J, McDermott MF, Savic S. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016. https:\/\/doi.org\/10.1172\/jci.insight.86336.","journal-title":"JCI Insight"},{"issue":"6","key":"1721_CR72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMc2031717","volume":"384","author":"AS Thomas","year":"2021","unstructured":"Thomas AS, Ma WJ, Wang YH. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med. 2021;384(6):581\u20133.","journal-title":"N Engl J Med"},{"issue":"9","key":"1721_CR73","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/ijms17091433","volume":"17","author":"J Fabre","year":"2016","unstructured":"Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Molecular Sci. 2016;17(9):1433. https:\/\/doi.org\/10.3390\/ijms17091433.","journal-title":"Int J Molecular Sci"},{"key":"1721_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rky001","author":"AR Oke","year":"2018","unstructured":"Oke AR, Wheater M, Karydis I, Wallis D. Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis. Rheumatol Adv Pract. 2018. https:\/\/doi.org\/10.1093\/rap\/rky001.","journal-title":"Rheumatol Adv Pract"},{"issue":"24","key":"1721_CR75","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1721_CR76","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","volume":"4","author":"J Leipe","year":"2018","unstructured":"Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, Skapenko A. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4(2): e000714.","journal-title":"RMD Open"},{"issue":"15","key":"1721_CR77","first-page":"1759","volume":"39","author":"J Luo","year":"2021","unstructured":"Luo J, Beattie J, Fuentes P, Rizvi H, Egger JV, Kern J, Hellmann MD. Beyond steroids: immunosuppressants in steroid-refractory\/resistant immune related adverse events. J Clin Oncol. 2021;39(15):1759.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1721_CR78","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Samuel D. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181\u201390.","journal-title":"J Hepatol"},{"issue":"1","key":"1721_CR79","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"T Peeraphatdit","year":"2020","unstructured":"Peeraphatdit T, Wang J, Odenwald MA, Hu SM, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72(1):315\u201329.","journal-title":"Hepatology"},{"issue":"2","key":"1721_CR80","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","volume":"34","author":"JV Cohen","year":"2021","unstructured":"Cohen JV, Dougan M, Zubiri L, Reynolds KL, Sullivan RJ, Misdraji J. Liver biopsy findings in patients on immune checkpoint inhibitors. Modern Pathol. 2021;34(2):426\u201337.","journal-title":"Modern Pathol"},{"issue":"8","key":"1721_CR81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/hepr.14078","volume":"54","author":"T Ito","year":"2024","unstructured":"Ito T, Takeuchi Y, Mizuno K, Imai M, Yoshimaru Y, Abe K, Tanaka A. Diagnostic guide for immune checkpoint inhibitor-induced liver injury. Hepatol Res. 2024;54(8):719\u201326.","journal-title":"Hepatol Res"},{"issue":"11","key":"1721_CR82","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","volume":"7","author":"M Li","year":"2021","unstructured":"Li M, Sack JS, Bell P, Rahma OE, Srivastava A, Grover S, Zucker SD. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol. 2021;7(11):1711\u20134.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1721_CR83","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14218\/JCTH.2021.00243","volume":"10","author":"N Hernandez","year":"2022","unstructured":"Hernandez N, Bessone F. Hepatotoxicity induced by biological agents: clinical features and current controversies. J Clin Transl Hepatol. 2022;10(3):486\u201395.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"1721_CR84","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","volume":"69","author":"ML Gauci","year":"2018","unstructured":"Gauci ML, Baroudjian B, Zeboulon C, Pages C, Pot\u00e9 N, Roux O, Grp P. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J Hepatol. 2018;69(2):548\u201350.","journal-title":"J Hepatol"},{"issue":"4","key":"1721_CR85","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.22.02270","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2023;41(4):715\u201323.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1721_CR86","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250\u20135.","journal-title":"Ann Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01721-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01721-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01721-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:59Z","timestamp":1764917459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01721-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01721-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to the publication of the article to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"288"}}